Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] by Urusaya Wangprasertkul, Arvemas Watcharakorn, Warit Tarathipmon, Varalee Mingkwansook

“…Results 129 cervical lymph nodes were collected from patients who met the inclusion criteria (50, 41, and 38 nodes from the lymphomatous, metastatic SCCA, and normal group, respectively). The mean ID of lymphomatous, metastatic SCCA, and normal nodes was 1.01±0.27, 1.36±0.28, and 1.45±0.29 mg/mL, respectively. …”
Get full text

Pathologic complete response following low-dose radiation for advanced oral cavity cancer in a patient with human immunodeficiency virus by Amy B. Leming, Andrea L. Johnston, Greg A. Krempl, Evan J. Fowle, Daniel J. Morton, Christina E. Henson

“…Abstract Background Advanced squamous cell carcinoma (SCCa) of the oral cavity is often not amenable to curative-intent therapy due to tumor location, tumor size, or comorbidities. …”
Get full text

Metastatic Status and Dissection Effect of Regional/Extraregional Lymph Nodes in Japanese Patients with Squamous Cell Carcinoma of the Anal Canal: A Multicenter Retrospective Cohor... by Takayuki Torigoe, Keiji Hirata, Kazutaka Yamada, Yoichi Ajioka, Kenichi Sugihara

“…Objectives: Squamous cell carcinoma of the anal canal (SCCA) is a rare condition. Standard treatment includes chemoradiotherapy, with surgical treatment reserved for limited cases. …”
Get full text

术前超敏C反应蛋白对评估宫颈鳞癌预后的价值

“…宫颈间质浸润深度?宫旁受累?患者年龄及治疗前hs-CRP和SCCA水平与宫颈鳞癌患者的无瘤生存期及总生存期相关;多因素分析显示仅肿瘤分期?淋巴结转移及治疗前hs-CRP水平与无瘤生存期及总生存期有关?…”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…The response rates in each cancer cohort were undifferentiated pleomorphic sarcoma 15% (n = 3/20; 95% CI 3–38%), salivary carcinoma 20% (n = 4/20; 95% CI: 6–44%), CUP 17% (n = 3/18; 95% CI 4–41%), SCCA 10% (n = 2/20; 95% CI 12–32%) and CCCO 21% (n = 8/39; 95% CI 9–37%). …”
Get full text